Screen2Prevent (S2P)
Part of paid clinical trials in Tampa, Florida.
- Sponsor
- Westat
- Study ID
- NCT07728123
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 14 Years - 24 Years
- Healthy Volunteers
- Accepted
Interventions
- HIV screening strategies — OTHERThe intervention includes three screening strategies (targeted, universally offered opt-in, and universally offered opt-out) which will each be employed, one at a time, for a period of 8 months. A targeted screening approach is defined as screening those who are at increased likelihood for acquiring HIV. Alternatively, a universally offered screening approach is defined as screening all, regardless of behavior informing risk. There are two types of universally offered screening, opt-in and opt-out. With opt-in screening, all patients are offered screening, which they may then agree to undergo. Opt-out screening consists of notifying patients that the test will be conducted unless they explicitly decline. Each screening strategy implements the cSHS, a text messaging platform, and Clinical Decision Support for identification of youth needing HIV treatment/prevention and linkage to services.
Study Details
Screen2Prevent is a study intended to improve HIV prevention and detection through implementation and evaluation of three different broad-scale HIV screening approaches a) targeted, b) universally offered opt-in, and c) universally offered opt-out in Emergency Departments (EDs) by leveraging digital health to identify and link adolescents seeking care in the ED to HIV Pre-Exposure Prophylaxis (PrEP)/Antiretroviral treatment (ART).
Key Dates
- First listed
- Jul 27, 2026
- Start date
- Jun 16, 2026
- Status verified
- Jul 2026
- Primary completion
- Oct 31, 2028
- Completion
- Oct 31, 2028
Study Design
- Enrollment
- 84,000 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SCREENING
Arms
- Other: 1. Universally offered opt-in > Universally offered opt-out > TargetedThe intervention includes three screening strategies (targeted, universally offered opt-in, and universally offered opt-out) which will each be employed, one at a time, for a period of 8 months.
- Other: 2. Universally offered opt-out > Universally offered opt-in > TargetedThe intervention includes three screening strategies (targeted, universally offered opt-in, and universally offered opt-out) which will each be employed, one at a time, for a period of 8 months.
- Other: 3. Universally offered opt-in > Targeted > Universally offered opt-outThe intervention includes three screening strategies (targeted, universally offered opt-in, and universally offered opt-out) which will each be employed, one at a time, for a period of 8 months.
- Other: 4. Universally offered opt-out > Targeted > Universally offered opt-inThe intervention includes three screening strategies (targeted, universally offered opt-in, and universally offered opt-out) which will each be employed, one at a time, for a period of 8 months.
- Other: 5. Targeted > Universally offered opt-out > Universally offered opt-inThe intervention includes three screening strategies (targeted, universally offered opt-in, and universally offered opt-out) which will each be employed, one at a time, for a period of 8 months.
- Other: 6. Targeted > Universally offered opt-in > Universally offered opt-outThe intervention includes three screening strategies (targeted, universally offered opt-in, and universally offered opt-out) which will each be employed, one at a time, for a period of 8 months.
Primary Outcome Measure
Monthly HIV detection rates per 1,000 eligible patients [ Time Frame: 36 months ]
Central Contacts
- Erin Ricketts240-453-2786
- Nancy Liu718-980-3937
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of South Florida | Tampa | Florida | 33612 | Carina Rodriguez, MD (PRINCIPAL_INVESTIGATOR) |
| Emory Atlanta Adolescent Consortium | Atlanta | Georgia | 30322 | Andres Camacho-Gonzalez, MD (PRINCIPAL_INVESTIGATOR) |
| Johns Hopkins University | Baltimore | Maryland | 21287 | Errol Fields, MD (PRINCIPAL_INVESTIGATOR) |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38015 | Aditya Gaur, MD (PRINCIPAL_INVESTIGATOR) |
| Baylor College of Medicine | Houston | Texas | 77030 | Mary Paul, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Tampa, FL
Nationwide
By condition
By specialty
Related Studies
- Skeletal Muscle Energetics and Fatiguability in Older IndividualsRecruiting · Johns Hopkins University · Baltimore, Maryland
- HIV Treatment Adherence Dose Determination TrialRecruiting · University of Connecticut · Storrs, Connecticut
- Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV PreventionRecruiting · Public Health Foundation Enterprises, Inc. · San Francisco, California
- Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCTPHASE2 · Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee